MDMA and psilocybin recently approved for medical use

The Therapeutic Goods Administration recently approved MDMA and psilocybin to treat mental illnesses.

“For the treatment of PTSD in the case of MDMA, and for the treatment of treatment-resistant depression in the case of psilocybin, these medicines will be reclassified as schedule eight, which means they are controlled drugs,” Neuromedicines Discovery Centre Deputy Director Professor Chris Langmead said.

“They’ll be able to be used in a clinical context in the same way, for example, that ketamine or other opioid analgesics are used in an operating theatre,” he told Sky News Australia.